TAM
CPRX

Telluride Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Telluride Asset Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-11,446
Closed -$22K – 255
2013
Q4 		$22K Buy
+11,446
New +$23.1K 0.03% 189

Other funds holding CPRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SC
Sophrosyne Capital New York $11.5M AUM 17.82% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCM
Tanaka Capital Management New York $59.9M AUM

Telluride Asset Management's CPRX Position: Q1 2014 in Review

Telluride Asset Management sold out of Catalyst Pharmaceutical (CPRX) in Q1 2014, closing a stake of 11,446 shares — an estimated $22K sold.

Telluride Asset Management first reported a position in CPRX in Q4 2013 and held it in 1 quarter. The position peaked at $22K in Q4 2013. 38 funds tracked by Wall St. Rank hold CPRX as of Q1 2014.

  • Telluride Asset Management reported no remaining Catalyst Pharmaceutical position as of Q1 2014 after selling out during the quarter.
  • Telluride Asset Management sold 11,446 Catalyst Pharmaceutical shares in Q1 2014, an estimated $22K.
  • Telluride Asset Management first reported a position in Catalyst Pharmaceutical in Q4 2013 and held it in 1 quarter.
  • Telluride Asset Management's Catalyst Pharmaceutical position peaked at $22K in Q4 2013.
  • 38 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2014.

Based on Telluride Asset Management's 13F filing for Q1 2014, filed 14 May 2014.